Immunorestoration of anergic cancer patients by azimexon

Azimexon, a new synthetic immunoadjuvant, can act on delayed-type hypersensitivity (DTH) reactions. Seven of 11 anergic cancer patients have been immunorestored by a relatively low dosage of azimexon. The effect on the lymphocyte responsiveness, and particularly of a new T-lymphocyte mitogen (TPA), are described. The possible mechanisms of the anergy of the cancer patients and of the mode of action of azimexon are discussed.